文献速递中枢神经肿瘤放疗姑息放疗与转移瘤放疗物理与技术

质子全中枢放疗在成人软脑膜病变中的早期经验

Early experience with proton craniospinal irradiation in adult patients with leptomeningeal disease.
PubMed 文献 · Radiat Oncol · 2025-04-22

该研究分析9例接受质子全中枢放疗(pCSI)的成人软脑膜病变(LMD)患者,中位年龄58.6岁、KPS 80%,中位PFS 2.7个月、CNS PFS 4.0个月、OS 4.0个月,未发生4级或5级毒性。作者认为pCSI对高度选择人群可能有效且安全,需进一步前瞻性研究。

要点

  • 9例成人LMD患者接受pCSI,均按计划完成治疗,中位随访3.5个月。
  • 中位PFS 2.7个月,CNS PFS 4.0个月,OS 4.0个月,随访期间6例死亡。
  • 年轻、较高KPS及同步靶向治疗与较长OS相关,脑和脊柱均受累者生存较短。

核心结论

  • pCSI对高度选择的LMD患者可能是一种有效且安全的治疗选择,需进一步数据与前瞻性研究明确其作用。

研究设计与样本

  • 单中心早期经验分析,纳入2023年2月至2024年2月接受pCSI的成人LMD患者,共9例符合分析条件。
  • 分析患者、肿瘤及治疗特征以及临床结局。

主要发现

  • 中位年龄58.6岁,中位KPS 80%,乳腺癌占33.3%,脑和脊柱均受累占55.5%。
  • 55.5%的患者治疗前接受脑脊液分流,几乎所有患者接受30 Gy(相对生物效应)分10次pCSI,全部按计划完成。
  • 临床与CNS影像中位随访均为3.5个月,随访期间观察到6例死亡。
  • 中位PFS 2.7个月,中位CNS PFS 4.0个月,中位OS 4.0个月。
  • 年轻、较高KPS及同步靶向治疗与较长OS相关,脑和脊柱均受累者生存较短。

临床怎么用

  • pCSI可作为高度选择LMD患者的治疗选择,治疗前需评估年龄、KPS及LMD受累范围。
  • 同步靶向治疗可能与较长OS相关,但需进一步研究确认。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Leptomeningeal disease (LMD) is a fatal complication of cancer linked to poor survival rates and limited treatment options. While photon involved-field radiotherapy is the standard of care for local palliation and symptom alleviation, it lacks durable disease control. Recent data suggest proton craniospinal irradiation (pCSI) to be a promising treatment option, potentially prolonging progression-free survival (PFS) and overall survival (OS). Herein, we report our initial experience with pCSI for treating LMD from solid malignancies. METHODS: Adult patients treated with pCSI for LMD were identified, with analysis of patient, tumor, and treatment characteristics as well as clinical outcomes. RESULTS: Nine patients were eligible for analysis who were treated between February 2023 and February 2024. The median age at pCSI and Karnofsky performance status (KPS) were 58.6 years and 80%, respectively. The primary disease was breast cancer in 33.3%, and LMD involved both the brain and spine in 55.5%. Approximately half of the patients (55.5%) had a cerebrospinal fluid diversion before treatment, and nearly all patients underwent pCSI with 30 Gy (relative biological effectiveness) in 10 fractions. All patients completed pCSI as planned. The median clinical and central nervous system (CNS) radiographic follow-up periods were both 3.5 months. Six deaths were observed during the available follow-up. The median PFS, CNS PFS, and OS were 2.7, 4.0, and 4.0 months, respectively. Younger age, higher KPS, and concurrent treatment with targeted therapy were associated with longer OS, while cases with LMD involving both the brain and spine had shorter survival. The observed toxicity was manageable, without any occurrence of grade 4 or 5 toxicity. CONCLUSION: pCSI can be an effective and safe treatment option for a highly selected population of patients with LMD. Further data and prospective studies are warranted to clarify its role in the management of LMD.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ehret F, Yuan AM, Marciscano AE, et al. Early experience with proton craniospinal irradiation in adult patients with leptomeningeal disease. Radiat Oncol. 2025. PMID: 40264106. doi:10.1186/s13014-025-02618-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。